AKRO vs. INSM: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at AKRO and INSM, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
INSM’s market capitalization of 18.58 billion USD is significantly greater than AKRO’s 4.13 billion USD, highlighting its more substantial market valuation.
INSM’s positive beta (0.79) suggests market-aligned movements, while AKRO with a negative beta (-0.16) tends to move counter to overall market trends, potentially acting as a defensive asset.
| Symbol | AKRO | INSM |
|---|---|---|
| Company Name | Akero Therapeutics, Inc. | Insmed Incorporated |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Medical - Pharmaceuticals |
| CEO | Andrew Cheng | William H. Lewis |
| Price | 51.77 USD | 97.8 USD |
| Market Cap | 4.13 billion USD | 18.58 billion USD |
| Beta | -0.16 | 0.79 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | June 20, 2019 | June 1, 2000 |
| ADR | No | No |
Historical Performance
This chart compares the performance of AKRO and INSM by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
AKRO
-31.98%
Biotechnology Industry
- Max
- 72.39%
- Q3
- -6.30%
- Median
- -32.82%
- Q1
- -68.26%
- Min
- -147.61%
AKRO has a negative Return on Equity of -31.98%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
INSM
-446.98%
Medical - Pharmaceuticals Industry
- Max
- -11.51%
- Q3
- -11.51%
- Median
- -28.40%
- Q1
- -54.57%
- Min
- -54.57%
INSM has a negative Return on Equity of -446.98%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Return on Invested Capital
AKRO
-27.35%
Biotechnology Industry
- Max
- 48.74%
- Q3
- -10.68%
- Median
- -31.65%
- Q1
- -52.92%
- Min
- -113.69%
AKRO has a negative Return on Invested Capital of -27.35%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.
INSM
-56.09%
Medical - Pharmaceuticals Industry
- Max
- 3.07%
- Q3
- 0.40%
- Median
- -9.25%
- Q1
- -9.31%
- Min
- -9.31%
INSM has a negative Return on Invested Capital of -56.09%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.
Net Profit Margin
AKRO
--
Biotechnology Industry
- Max
- 87.75%
- Q3
- -5.05%
- Median
- -103.44%
- Q1
- -1,032.77%
- Min
- -2,366.07%
Net Profit Margin data for AKRO is currently unavailable.
INSM
-265.93%
Medical - Pharmaceuticals Industry
- Max
- -3.80%
- Q3
- -5.21%
- Median
- -8.76%
- Q1
- -9.40%
- Min
- -9.40%
INSM has a negative Net Profit Margin of -265.93%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin
AKRO
--
Biotechnology Industry
- Max
- 87.75%
- Q3
- -3.28%
- Median
- -115.26%
- Q1
- -1,188.86%
- Min
- -2,943.30%
Operating Profit Margin data for AKRO is currently unavailable.
INSM
-230.21%
Medical - Pharmaceuticals Industry
- Max
- 4.55%
- Q3
- 0.04%
- Median
- -2.01%
- Q1
- -7.08%
- Min
- -7.08%
INSM has a negative Operating Profit Margin of -230.21%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | AKRO | INSM |
|---|---|---|
| Return on Equity (TTM) | -31.98% | -446.98% |
| Return on Assets (TTM) | -23.31% | -56.21% |
| Return on Invested Capital (TTM) | -27.35% | -56.09% |
| Net Profit Margin (TTM) | -- | -265.93% |
| Operating Profit Margin (TTM) | -- | -230.21% |
| Gross Profit Margin (TTM) | -- | 76.16% |
Financial Strength
Current Ratio
AKRO
16.80
Biotechnology Industry
- Max
- 28.73
- Q3
- 13.97
- Median
- 6.31
- Q1
- 3.60
- Min
- 0.02
AKRO’s Current Ratio of 16.80 is in the upper quartile for the Biotechnology industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
INSM
5.86
Medical - Pharmaceuticals Industry
- Max
- 2.08
- Q3
- 2.08
- Median
- 1.96
- Q1
- 0.82
- Min
- 0.61
INSM’s Current Ratio of 5.86 is exceptionally high, placing it well outside the typical range for the Medical - Pharmaceuticals industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.
Debt-to-Equity Ratio
AKRO
0.01
Biotechnology Industry
- Max
- 0.46
- Q3
- 0.22
- Median
- 0.06
- Q1
- 0.02
- Min
- 0.00
Falling into the lower quartile for the Biotechnology industry, AKRO’s Debt-to-Equity Ratio of 0.01 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
INSM
11.53
Medical - Pharmaceuticals Industry
- Max
- 11.35
- Q3
- 6.06
- Median
- 3.76
- Q1
- 2.54
- Min
- 0.28
With a Debt-to-Equity Ratio of 11.53, INSM operates with exceptionally high leverage compared to the Medical - Pharmaceuticals industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
Interest Coverage Ratio
AKRO
-121.42
Biotechnology Industry
- Max
- 108.32
- Q3
- -0.55
- Median
- -8.49
- Q1
- -74.83
- Min
- -168.36
AKRO has a negative Interest Coverage Ratio of -121.42. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
INSM
-10.72
Medical - Pharmaceuticals Industry
- Max
- 1.42
- Q3
- 0.39
- Median
- -3.07
- Q1
- -7.31
- Min
- -10.72
INSM has a negative Interest Coverage Ratio of -10.72. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | AKRO | INSM |
|---|---|---|
| Current Ratio (TTM) | 16.80 | 5.86 |
| Quick Ratio (TTM) | 16.80 | 5.44 |
| Debt-to-Equity Ratio (TTM) | 0.01 | 11.53 |
| Debt-to-Asset Ratio (TTM) | 0.01 | 0.63 |
| Net Debt-to-EBITDA Ratio (TTM) | 0.65 | -0.80 |
| Interest Coverage Ratio (TTM) | -121.42 | -10.72 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for AKRO and INSM. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
AKRO
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
AKRO currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
INSM
0.00%
Medical - Pharmaceuticals Industry
- Max
- 11.18%
- Q3
- 4.37%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INSM currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio
AKRO
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
AKRO has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
INSM
0.00%
Medical - Pharmaceuticals Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INSM has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | AKRO | INSM |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio
AKRO
-15.11
Biotechnology Industry
- Max
- 78.44
- Q3
- 48.98
- Median
- 20.50
- Q1
- 12.64
- Min
- 2.14
AKRO has a negative P/E Ratio of -15.11. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.
INSM
-17.46
Medical - Pharmaceuticals Industry
- Max
- --
- Q3
- --
- Median
- --
- Q1
- --
- Min
- --
INSM has a negative P/E Ratio of -17.46. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.
Forward P/E to Growth Ratio
AKRO
0.68
Biotechnology Industry
- Max
- 2.29
- Q3
- 1.10
- Median
- 0.49
- Q1
- 0.16
- Min
- 0.02
AKRO’s Forward PEG Ratio of 0.68 is within the middle range of its peers in the Biotechnology industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.
INSM
2.71
Medical - Pharmaceuticals Industry
- Max
- 2.76
- Q3
- 2.07
- Median
- 1.38
- Q1
- 0.69
- Min
- 0.00
A Forward PEG Ratio of 2.71 places INSM in the upper quartile for the Medical - Pharmaceuticals industry. This suggests the stock is potentially expensive compared to its peers relative to its growth forecast, which may warrant caution.
Price-to-Sales Ratio
AKRO
--
Biotechnology Industry
- Max
- 110.90
- Q3
- 59.76
- Median
- 11.33
- Q1
- 4.45
- Min
- 0.17
P/S Ratio data for AKRO is currently unavailable.
INSM
48.76
Medical - Pharmaceuticals Industry
- Max
- 5.74
- Q3
- 5.74
- Median
- 5.66
- Q1
- 2.83
- Min
- 0.07
With a P/S Ratio of 48.76, INSM trades at a valuation that eclipses even the highest in the Medical - Pharmaceuticals industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio
AKRO
3.76
Biotechnology Industry
- Max
- 15.78
- Q3
- 7.44
- Median
- 3.31
- Q1
- 1.58
- Min
- 0.31
The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.
INSM
178.38
Medical - Pharmaceuticals Industry
- Max
- 130.20
- Q3
- 55.61
- Median
- 10.51
- Q1
- 5.88
- Min
- 1.39
The P/B Ratio is often not a primary valuation metric for the Medical - Pharmaceuticals industry.
Valuation at a Glance
| Symbol | AKRO | INSM |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -15.11 | -17.46 |
| Forward PEG Ratio (TTM) | 0.68 | 2.71 |
| Price-to-Sales Ratio (P/S, TTM) | -- | 48.76 |
| Price-to-Book Ratio (P/B, TTM) | 3.76 | 178.38 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -15.71 | -23.54 |
| EV-to-EBITDA (TTM) | -14.31 | -20.76 |
| EV-to-Sales (TTM) | -- | 50.70 |